Natco Pharma Ltd and its US partner Allergan have announce settlement of the pending litigation with Celgene regarding generic Lenalidomide (Revlimed) capsules.
Celgene has agreed to provide Natco with a licence to Celgene’s patents required to manufacture and sell an unlimited quantity of generic Lenalidomide capsules in the United States beginning on January 31, 2026, Natco Pharma informed the BSE.
In addition, Natco will receive a volume-limited licence to sell generic Lenalidomide in the United States commencing in March 2022. The volume limit is expected to be a mid-single-digit percentage of the total Lenalidomide capsules dispensed in the United States during the first full year of entry.
The volume limitation is expected to increase gradually each 12 months until March of 2025, and is not expected to exceed one-third of the total Lenalidomide capsules dispensed in the US in the final year of the volume-limited licence under this agreement.
Revlimed had recorded sales of nearly $ 3.4 billion in the US market for the year ending September 2015.